메뉴 건너뛰기




Volumn 27, Issue 5, 2011, Pages 557-567

Safety and immunogenicity of the MRKAd5 gag HIV type 1 vaccine in a worldwide phase 1 study of healthy adults

(19)  Nicholson, Ouzama a,b   Dicandilo, Fay a,b   Kublin, James c   Sun, Xiao a,b   Quirk, Erin a,b   Miller, Michelle a,b   Gray, Glenda d   Pape, Jean e   Robertson, Michael N a,b   Mehrotra, Devan V a,b   Self, Steven c   Turner, Katherine c   Sanchez, Jorge f,g   Pitisuttithum, Punnee h   Duerr, Ann c,i   Dubey, Sheri a,b   Kierstead, Lisa a,b   Casimiro, Danilo a,b   Hammer, Scott M j  


Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIBODY; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO;

EID: 79955774295     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2010.0151     Document Type: Article
Times cited : (19)

References (78)
  • 2
    • 33750524856 scopus 로고    scopus 로고
    • The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world
    • Bennett DE: The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world. Curr Opin Infect Dis 2006;19:607-614.
    • (2006) Curr Opin Infect Dis , vol.19 , pp. 607-614
    • De, B.1
  • 6
    • 38449105585 scopus 로고    scopus 로고
    • Antiretroviral resistance mutations in untreated pregnant women with HIV infection in Uganda and Rwanda [letter to the editor]
    • Galluzzo CM, Germinario EAP, Bassani L, et al.: Antiretroviral resistance mutations in untreated pregnant women with HIV infection in Uganda and Rwanda [letter to the editor]. AIDS Res Hum Retroviruses 2007;23:1449-1451.
    • (2007) AIDS Res Hum Retroviruses , vol.23 , pp. 1449-1451
    • Galluzzo, C.M.1    Eap, G.2    Bassani, L.3
  • 9
    • 38149109662 scopus 로고    scopus 로고
    • Molecular characterization of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in Yaounde, Cameroon: Evidence of major drug resistance mutations in newly diagnosed patients infected with subtypes other than subtype B
    • Ndembi N, Abraha A, Pilch H, et al.: Molecular characterization of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in Yaounde, Cameroon: Evidence of major drug resistance mutations in newly diagnosed patients infected with subtypes other than subtype B. J Clin Microbiol 2008;46:177-184.
    • (2008) J Clin Microbiol , vol.46 , pp. 177-184
    • Ndembi, N.1    Abraha, A.2    Pilch, H.3
  • 13
    • 33750587775 scopus 로고    scopus 로고
    • Risky sexual behaviors of adolescents in rural Malawi: Evidence from focus groups
    • Dancy BL, Kaponda CPN, Kachingwe SI, and Norr KF: Risky sexual behaviors of adolescents in rural Malawi: Evidence from focus groups. J Natl Black Nurses Assoc 2006;17:22-28.
    • (2006) J Natl Black Nurses Assoc , vol.17 , pp. 22-28
    • Dancy, B.L.1    Cpn, K.2    Kachingwe, S.I.3    Norr, K.F.4
  • 14
    • 40949154387 scopus 로고    scopus 로고
    • Evidence-based efforts to prevent HIV infection: An overview of current status and future challenges
    • DOI 10.1086/522553
    • Holtgrave D: Evidence-based efforts to prevent HIV infection: An overview of current status and future challenges. Clin Infect Dis 2007;45:S293-S299. (Pubitemid 351417232)
    • (2007) Clinical Infectious Diseases , vol.45 , Issue.SUPPL. 4
    • Holtgrave, D.1
  • 15
    • 33645812933 scopus 로고    scopus 로고
    • What works, and what remains to be done, in HIV prevention in the United States
    • Holtgrave DR and Curran JW: What works, and what remains to be done, in HIV prevention in the United States. Annu Rev Public Health 2006;27:261-275.
    • (2006) Annu Rev Public Health , vol.27 , pp. 261-275
    • Holtgrave, D.R.1    Curran, J.W.2
  • 16
    • 39749127343 scopus 로고    scopus 로고
    • "Bundling" HIV prevention: Integrating services to promote synergistic gain
    • DOI 10.1016/j.ypmed.2007.09.006, PII S0091743507004161
    • Ickovics JR: "Bundling" HIV prevention: Integrating services to promote synergistic gain. Prev Med 2008;46:222-225. (Pubitemid 351308148)
    • (2008) Preventive Medicine , vol.46 , Issue.3 , pp. 222-225
    • Ickovics, J.R.1
  • 17
    • 23944492639 scopus 로고    scopus 로고
    • From treatment to prevention: The interplay between HIV/AIDS treatment availability and HIV/AIDS prevention programming in Khayelitsha, South Africa
    • DOI 10.1093/jurban/jti090
    • Levy NC, Miksad RA, and Fein OT: From treatment to prevention: The interplay between HIV/AIDS treatment availability and HIV/AIDS prevention programming in Khayelitsha, South Africa. J Urban Health 2005;82:498-509. (Pubitemid 41191568)
    • (2005) Journal of Urban Health , vol.82 , Issue.3 , pp. 498-509
    • Levy, N.C.1    Miksad, R.A.2    Fein, O.T.3
  • 20
    • 34548357053 scopus 로고    scopus 로고
    • The dynamics of intergenerational sexual relationships: The experience of schoolgirls in Botswana
    • DOI 10.1071/SH06070
    • Nkosana J and Rosenthal D: The dynamics of intergeneraltional sexual relationships: The experience of schoolgirls in Botswana. Sex Health 2007;4:181-187. (Pubitemid 47339636)
    • (2007) Sexual Health , vol.4 , Issue.3 , pp. 181-187
    • Nkosana, J.1    Rosenthal, D.2
  • 21
    • 33947631339 scopus 로고    scopus 로고
    • Modelling the public health impact of male circumcision for HIV prevention in high prevalence area in Africa
    • Nagelkerke NJD, Moses S, de Vlas SJ, and Bailey RC: Modelling the public health impact of male circumcision for HIV prevention in high prevalence area in Africa. BMC Infect Dis 2007;7:16.
    • (2007) BMC Infect Dis , vol.7 , pp. 16
    • Njd, N.1    Moses, S.2    De Vlas, S.J.3    Bailey, R.C.4
  • 22
    • 33846018595 scopus 로고    scopus 로고
    • Circumcision and HIV transmission
    • DOI 10.1097/QCO.0b013e328012c5bc, PII 0000143220070200000007
    • Quinn TC: Circumcision and HIV transmission. Curr Opin Infect Dis 2007;20:33-38. (Pubitemid 46052124)
    • (2007) Current Opinion in Infectious Diseases , vol.20 , Issue.1 , pp. 33-38
    • Quinn, T.C.1
  • 23
    • 34248191210 scopus 로고    scopus 로고
    • The Future of HIV Prevention: Control of Sexually Transmitted Infections and Circumcision Interventions
    • DOI 10.1016/j.idc.2007.03.005, PII S0891552007000189
    • Sahasrabuddhe VV and Vermund SH: The future of HIV prevention: Control of sexually transmitted infections and circumcision interventions. Infect Dis Clin North Am 2007;21:241-257. (Pubitemid 46719805)
    • (2007) Infectious Disease Clinics of North America , vol.21 , Issue.1 , pp. 241-257
    • Sahasrabuddhe, V.V.1    Vermund, S.H.2
  • 26
    • 33847104829 scopus 로고    scopus 로고
    • Male circumcision for HIV prevention in men in Rakai Uganda: A randomised trial
    • Gray RH, Kigozi G, Serwadda D, et al.: Male circumcision for HIV prevention in men in Rakai, Uganda: A randomised trial. Lancet 2007;369:657-666.
    • (2007) Lancet , vol.369 , pp. 657-666
    • Gray, R.H.1    Kigozi, G.2    Serwadda, D.3
  • 27
    • 77955930318 scopus 로고    scopus 로고
    • Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women
    • Karim Q, Karim S, Frohlich J, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168-1174.
    • (2010) Science , vol.329 , pp. 1168-1174
    • Karim, Q.1    Karim, S.2    Frohlich, J.3
  • 28
    • 33749019447 scopus 로고    scopus 로고
    • Modeling the impact of a partially effective HIV vaccine on HIV infection and death among women and infants in South Africa
    • DOI 10.1097/01.qai.0000230526.79341.83, PII 0012633420061001000013
    • Amirfar S, Hollenberg JP, and Abdool Karim SS: Modeling the impact of a partially effective HIV vaccine on HIV infection and death among women and infants in South Africa. J Acquir Immune Defic Syndr 2006;43:219-225. (Pubitemid 44454817)
    • (2006) Journal of Acquired Immune Deficiency Syndromes , vol.43 , Issue.2 , pp. 219-225
    • Amirfar, S.1    Hollenberg, J.P.2    Abdool Karim, S.S.3
  • 29
    • 34848910202 scopus 로고    scopus 로고
    • Predicting the impact of a partially effective HIV vaccine and subsequent risk behavior change on the heterosexual HIV epidemic in low- and middle-income countries: A South African example
    • DOI 10.1097/QAI.0b013e31812506fd, PII 0012633420070901000012
    • Andersson KM, Owens DK, Vardas E, Gray GE, McIntyre JA, and Paltiel AD: Predicting the impact of a partially effective HIV vaccine and subsequent risk behavior change on the heterosexual HIV epidemic in low- and middle-income countries: A South African example. J Acquir Immune Defic Syndr 2007;46:78-90. (Pubitemid 47507437)
    • (2007) Journal of Acquired Immune Deficiency Syndromes , vol.46 , Issue.1 , pp. 78-90
    • Andersson, K.M.1    Owens, D.K.2    Vardas, E.3    Gray, G.E.4    McIntyre, J.A.5    Paltiel, A.D.6
  • 30
    • 22144441378 scopus 로고    scopus 로고
    • Predicting the potential public health impact by disease-modifying HIV vaccines in South Africa: The problem of subtypes
    • DOI 10.2174/1568005054201616
    • Blower SM, Bodine EN, and Grovit-Ferbas K: Predicting the potential public health impact of disease-modifying HIV vaccines in South Africa: The problem of subtypes. Curr Drug Targets 2005;5:179-192. (Pubitemid 40974797)
    • (2005) Current Drug Targets - Infectious Disorders , vol.5 , Issue.2 , pp. 179-192
    • Blower, S.M.1    Bodine, E.N.2    Grovit-Ferbas, K.3
  • 31
    • 4043060710 scopus 로고    scopus 로고
    • Correlates of immune protection in HIV-1 infection: What we know, what we don't know, what we should know
    • DOI 10.1038/nm0804-806
    • Pantaleo G and Koup RA: Correlates of immune protection in HIV-1 infection: What we know, what we don't know, what we should know. Nat Med 2004;10:806-810. (Pubitemid 39070851)
    • (2004) Nature Medicine , vol.10 , Issue.8 , pp. 806-810
    • Pantaleo, G.1    Koup, R.A.2
  • 37
    • 34249339797 scopus 로고    scopus 로고
    • Cornering HIV: Taking advantage of interactions between selective pressures
    • DOI 10.1016/j.mehy.2006.12.012, PII S0306987706009145
    • Á vila-Ríos S, Reyes-Terán G, and Espinosa E: Cornering HIV: Taking advantage of interactions between selective pressures. Med Hypotheses 2007;69:422-431. (Pubitemid 46818696)
    • (2007) Medical Hypotheses , vol.69 , Issue.2 , pp. 422-431
    • Avila-Rios, S.1    Reyes-Teran, G.2    Espinosa, E.3
  • 39
    • 0036319711 scopus 로고    scopus 로고
    • Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy
    • DOI 10.1016/S1473-3099(02)00343-2
    • Thomson MM, Pérez-Á varez L, Ná jera R: Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis 2002; 2:461-471. (Pubitemid 34826851)
    • (2002) Lancet Infectious Diseases , vol.2 , Issue.8 , pp. 461-471
    • Thomson, M.M.1    Perez-Alvarez, L.2    Najera, R.3
  • 41
    • 13944254982 scopus 로고    scopus 로고
    • Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection
    • The rgp120 HIV Vaccine Study Group
    • The rgp120 HIV Vaccine Study Group: Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005;191:654-665.
    • (2005) J Infect Dis , vol.191 , pp. 654-665
  • 45
    • 0034692516 scopus 로고    scopus 로고
    • Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines
    • Ferrari G, Kostyu DD, Cox J, et al.: Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines. AIDS Res Hum Retroviruses 2000;16:1433-1443.
    • (2000) AIDS Res Hum Retroviruses , vol.16 , pp. 1433-1443
    • Ferrari, G.1    Kostyu, D.D.2    Cox, J.3
  • 46
    • 0037192588 scopus 로고    scopus 로고
    • Cytotoxic T-cell recognition of HIV-1 cross-clade and clade-specific epitopes in HIV-1-infected Thai and Japanese patients
    • DOI 10.1097/00002030-200203290-00005
    • Fukada K, Tomiyama H, Wasi C, et al.: Cytotoxic T-cell recognition of HIV-1 cross-clade and clade-specific epitopes in HIV-1-infected Thai and Japanese patients. AIDS 2002; 16:701-711. (Pubitemid 34274460)
    • (2002) AIDS , vol.16 , Issue.5 , pp. 701-711
    • Fukada, K.1    Tomiyama, H.2    Wasi, C.3    Matsuda, T.4    Kusagawa, S.5    Sato, H.6    Oka, S.7    Takebe, Y.8    Takiguchi, M.9
  • 54
    • 0033394054 scopus 로고    scopus 로고
    • Efficient human immunodeficiency virus (HIV)-1 Gag-Env pseudovirion formation elicited from mammalian cells by a canarypox HIV vaccine candidate
    • DOI 10.1086/315028
    • Fang Z-Y, Kuli-Zade I, and Spearman P: Efficient human immunodeficiency virus (HIV)-1 gag-env pseudovirion formation elicited from mammalian cells by a canarypox HIV vaccine candidate. J Infect Dis 1999;180:1122-1132. (Pubitemid 30070195)
    • (1999) Journal of Infectious Diseases , vol.180 , Issue.4 , pp. 1122-1132
    • Fang, Z.-Y.1    Kuli-Zade, I.2    Spearman, P.3
  • 67
    • 42049115708 scopus 로고    scopus 로고
    • Efficacy results from the STEP Study (Merck V520 Protocol 023/HVTN 502): A phase II test-of-concept trial of the MRKAd5 HIV-1 Gag/Pol/Nef Trivalent Vaccine
    • Abstract 88LB
    • Robertson M, Mehrotra D, Fitzgerald D, et al.: Efficacy results from the STEP Study (Merck V520 Protocol 023/HVTN 502): A phase II test-of-concept trial of the MRKAd5 HIV-1 Gag/Pol/Nef Trivalent Vaccine. 15th Conference on Retroviruses and Opportunistic Infections 2008. Abstract 88LB.
    • (2008) 15th Conference on Retroviruses and Opportunistic Infections
    • Robertson, M.1    Mehrotra, D.2    Fitzgerald, D.3
  • 68
    • 56649105122 scopus 로고    scopus 로고
    • Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebocontrolled, test-of-concept trial
    • Buchbinder SP, Mehrotra DV, Duerr A, et al.: Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebocontrolled, test-of-concept trial. Lancet 2008;372:1881-1893.
    • (2008) Lancet , vol.372 , pp. 1881-1893
    • Buchbinder, S.P.1    Mehrotra, D.V.2    Duerr, A.3
  • 69
    • 73349094086 scopus 로고    scopus 로고
    • Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
    • Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209-2220.
    • (2009) N Engl J Med , vol.361 , pp. 2209-2220
    • Rerks-Ngarm, S.1    Pitisuttithum, P.2    Nitayaphan, S.3
  • 70
    • 77954920017 scopus 로고    scopus 로고
    • Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
    • Wu X, Yang ZY, Liang Y, et al.: Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010;329(5993):856-861.
    • (2010) Science , vol.329 , Issue.5993 , pp. 856-861
    • Wu, X.1    Yang, Z.Y.2    Liang, Y.3
  • 71
    • 60549106905 scopus 로고    scopus 로고
    • Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults
    • Harro CD, Robertson MN, Lally MA, et al.: Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults. AIDS Res Hum Retroviruses 2009;25:1-12.
    • (2009) AIDS Res Hum Retroviruses , vol.25 , pp. 1-12
    • Harro, C.D.1    Robertson, M.N.2    Ma, L.3
  • 75
    • 0021832508 scopus 로고
    • Comparative analysis of two rates
    • Miettinen O and Nurminen M: Comparative analysis of two rates. Stat Med 1985;4:213-226. (Pubitemid 15055349)
    • (1985) Statistics in Medicine , vol.4 , Issue.2 , pp. 213-226
    • Miettinen, O.1    Nurminen, M.2
  • 76
    • 2942527313 scopus 로고    scopus 로고
    • Use of the false discovery rate for evaluating clinical safety data
    • Mehrotra DV and Heyse JF: Use of the false discovery rate for evaluating clinical safety data. Stat Methods Med Res 2004;13:227-238. (Pubitemid 38744605)
    • (2004) Statistical Methods in Medical Research , vol.13 , Issue.3 , pp. 227-238
    • Mehrotra, D.V.1    Heyse, J.F.2
  • 78
    • 56749096265 scopus 로고    scopus 로고
    • HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine
    • Quirk EK, Mogg R, Brown DD, et al.: HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine. Clin Infect Dis 2008;47:1593-1599.
    • (2008) Clin Infect Dis , vol.47 , pp. 1593-1599
    • Quirk, E.K.1    Mogg, R.2    Brown, D.D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.